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International Journal of Women's DermatologyLetter to the EditorConsiderations on biologic agents in psoriasis with the new pregnancy
lactation labeling rule☆Psoriasis is a complex chronic disease that can be challenging to
manage, especially during pregnancy. The course of psoriasis can
ﬂuctuate throughout pregnancy as hormone levels change. In the
only prospective study of pregnant patients with psoriasis, it was
found that 55% of the patients reported improvement during preg-
nancy, 21% reported no change, and 23% reported worsening of pso-
riasis. However, postpartum, only 9% of patients reported
improvement, 26% reported no change, and 65% reported worsening
psoriasis. High levels of estrogen correlated with improvement in
psoriasis, whereas progesterone levels did not correlate with psoriat-
ic change (Murase et al., 2005).
It is now well known that Th1 and Th17 immunity plays a role in
the current model of psoriasis pathogenesis. It has also been shown
that pregnancy can be associated with diminished Th1 and Th17me-
diated immunity, mainly due to the effects of increased estradiol. It is
postulated that this increase promotes fetal survival by decreasing re-
sponses involved in rejection of the fetus (Sacks et al., 2001; Santner-
Nanan et al., 2009). With all of these dynamics at play, it can be difﬁ-
cult for dermatologists to manage psoriasis in pregnant patients
while protecting the fetus and mother.
When identifying medications and treatments to use in psoriasis
patients during pregnancy, the old lettering categories of A, B, C, D,
andX have served as surrogatemarkers of risk stratiﬁcation. A review
of treatment options for pregnant psoriasis patients found that most
treatment options fall under category C, indicating that controlled
studies in humans either have not been performed or are not avail-
able (Bae et al, 2012). Additionally, the 2012 National Psoriasis Foun-
dation (NPF) consensus guidelines for treatment of all psoriasis
patients propose ﬁrst-line treatment with moisturizers and topical
corticosteroids (preferably low to mid potency); second-line treat-
ment with narrowband or broadband ultraviolet B; and third-line
treatment with tumor necrosis factor inhibitors (adalimumab,
etanercept, inﬂiximab), cyclosporine, or systemic steroids (in second
and third trimesters only). TheNPF guidelines also state that systemic
and biologic agents should be avoided in pregnancy and lactation un-
less there is a clear medical need (Chi et al., 2010). However, two
major changes have occurred since the release of these guidelines
that dermatologists should take into consideration. The introduction
of a new pregnancy safety labeling system and the surge of newer bi-
ologic agents for the treatment of psoriasis into the marketplace will
affect treatment options for pregnant patients.
Dermatologists should be knowledgeable about the recent Food
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creativecommons.org/licenses/by-nc-nd/4.0/).is labeled on drugs. Effective June 30, 2015, the FDA released their
Pregnancy and Lactation Labeling Rule (PLLR) which will be phased
in over the next 3 years for existing drugs and required for all new
drugs. The PLLRwill introduce changes that aim to improve the com-
munication and decision-making process between physicians and
patients. The PLLR has several main changes, including the removal
of pregnancy lettering categories; compression of population catego-
ries (e.g., pregnancy, labor and delivery, nursing mothers); and the
implementation of a new risk narrative section. The PLLRwill abolish
lettering categories entirely and replace themwith an individualized
narrative summary of each drug which will include “risks of using a
drug during pregnancy and lactation, a discussion of the data
supporting that summary, and relevant information to help health
care providers make prescribing decisions and counsel women
about the use of drugs during pregnancy and lactation” (FDA,
2014). It will also create new populations labels, with the former la-
bels of “Pregnancy” and “Labor and Delivery” being combined and
placed into a single category of “Pregnancy.” The former population
label of “Nursing Mothers”will now be placed into the label of “Lac-
tation.” Additionally, there will be an entirely new label of “Females
and Males of Reproductive Potential,” which will discuss contracep-
tion recommendations, pregnancy testing, and information sur-
rounding infertility associated with medication use.
The new changes introduced by the PLLR will aim to improve the
former pregnancy lettering system, which has been criticized for
being overly simpliﬁed, ambiguous, and incomplete (Addis et al.,
2000; Boothby and Doering, 2000; Doering et al., 2002). This new
narrative system will not only remove some of the prior ambiguity
from the lettering system, but it will also present more information
for physicians and patients to create a more individualized clinical
decision. Additionally, this will help to reduce the “innocent until
proven guilty” status that is placed on drugs, where untested drugs
without any known harmful side effects are perceived to be safer
(category B) than tested drugs with known side effects (category
C). This narrative will provide more explicit detail on the sources of
information and data pertaining to drugs. For example, the pharma-
ceutical drug pregnancy data information is obtained from animal
studies in 92.9% of drugs, and only 5.2% obtained from human preg-
nancy data (Chambers, 2014; FDA, 1999; Mazer-Amirshahi et al,
2014). This kind of informationwill bemade explicit in the new PLLR.
Since the last NPF guidelines on treatment of psoriasis in pregnan-
cy were released in 2012, new biologic agents have come to market,
with many more in the research pipeline. Currently, two new agents
are on the market: an anti–interleukin (IL)-17 agent, secukinumab,
approved for moderate to severe plaque psoriasis in January 2015;
and the small molecular inhibitor, apremilast, a phosphodiesteraseologic Society. This is an open access article under the CC BY-NC-ND license (http://
61Letter to the Editor4 inhibitor approved for moderate to severe plaque psoriasis in Sep-
tember 2014. Many other biologic agents and small molecule inhibi-
tors are in the pipeline: anti–IL-17 agents such as ixekizumab, and
brodalumab, and anti–IL-23 agents such as tildrakizumab and
guselkumab (Mansouri and Goldenberg, 2015). Although phase 2
and 3 data from these drugs show very promising results for the
treatment of psoriasis, additional considerations must be taken
when treating pregnant psoriasis patients (Grifﬁths et al., 2015;
Langley et al., 2015; Lebwohl et al., 2015). From these preliminary re-
sults, it appears that these drugs have similar safety proﬁles, with the
most frequently reported adverse events being nasopharyngitis,
upper respiratory infections, headache, and injection site reaction
(Mansouri and Goldenberg, 2015). These adverse events are similar
to those seen in older biologic agents such as adalimumab,
etanercept, and inﬂiximab (Mendes et al., 2014).
Few data are available evaluating the safety in pregnancy for
adalimumab, etanercept, and inﬂiximab,with an even further paucity
of data regarding the newer biologic agents discussed. Several case
series, case reports, and retrospective studies have concluded that
adalimumab, etanercept, and inﬂiximab have all been consistent
with the old FDA categorization of pregnancy class B (Berthelot
et al., 2009; Carter et al., 2006; Kane et al., 2009; Katz et al., 2004;
Mahadevan et al., 2005; Mishkin et al., 2006; Murashima et al.,
2009; Rump and Schönborn, 2010). This is all consistent with the
2012 NPF recommendations that these drugs should be regarded as
third-line treatments for pregnant psoriasis patients (Bae et al.,
2012). For these reasons and the changing PLLR classiﬁcation system,
we propose to update the recommendations to include the newest
generation of biologic agents for psoriasis. Given that the advent of
the newest generation of biologics is not mentioned in the 2012
guidelines, we endorse the extension of the same recommendations
to all pregnant psoriasis patients for the anti–IL-17 agents
(secukinumab, brodalumab, ixekizumab) and anti–IL-23 agents (BI
655066, guselkumab, tildrakizumab). These drugs, which are either
currently on the market or in the pipeline, have demonstrated theo-
retical immunosuppressive risk and safety proﬁles similar to the pre-
vious generation of biologics and should be considered as such in
pregnant psoriasis patients (Manalo et al., 2015; Mansouri and
Goldenberg, 2015).
Although the new PLLR labeling system will provide additional
narrative and data to the selection process of drugs in pregnancy, it
will take time before adequate data are available to construct an ac-
ceptable narrative. Until all of the data are in, it may be the best
course of action to continue with ﬁrst- and second-line treatment
modalities for pregnant psoriasis patients and consider the new bio-
logic agents as third-line treatment options. All physicians are en-
couraged to review the new labeling rules (Federal Register, 2014)
in order to promote a smooth transition. For a more condensed ver-
sion of the PLLR, please see U.S. Department of Health and Human
Services (2014). Drug labels may be found at Dailymed (http://
dailymed.nlm.nih.gov/dailymed/index.cfm).
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